This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Tsai, Y. C. Articles by Jones, P. A. Search for Related Content PubMed Articles by Tsai, Y. C. Articles by Jones, P. A.

Allelic Losses of Chromosomes 9, 11, and 17 in Human Bladder Cancer¹

Urologic Cancer Research Laboratory, Kenneth Norris Jr. Comprehensive Cancer Center, University of Southern California School of Medicine, Los Angeles, California 90033

Twenty-five human bladder tumors were examined for loss of heterozygosity of markers on chromosomes 6p, 9q, 11p, 14q, and 17p. These studies show that all of the markers were reduced to homozygosity in at least some of the tumors. They also confirmed earlier studies by Fearon et al. [Nature (Lond.), 318: 377–380, 1985] that approximately 40% of bladder tumors were reduced to homozygosity for markers on chromosome 11p. However, the greatest frequency of allelic loss was seen for chromosomes 9q (67% of informative cases) and 17p (63% of informative cases) with both chromosomes being lost concordantly in 10 out of 20 informative tumors. Allelic loss of chromosome 9q has not been previously observed with other human cancers; however, deletions of 17p have been reported in breast, lung, and colorectal carcinomas. The data raise the interesting possibility that allelic losses of specific chromosomes might be a feature of cancer in a particular differentiated cell type whereas loss of other chromosomes harboring more generally acting tumor suppressor genes might be a common feature of human cancers.

¹ This work was supported by an Outstanding Investigator Grant from the National Cancer Institute to P. A. J. (R35 CA49758) and a research grant from the Cancer Research Society, Redlands Branch.

² To whom requests for reprints should be addressed.

Received 7/14/89. Revised 10/ 2/89. Accepted 10/ 4/89.

This article has been cited by other articles:

				M. A. Knowles Molecular subtypes of bladder cancer: Jekyll and Hyde or chalk and cheese? Carcinogenesis, March 1, 2006; 27(3): 361 - 373. [Abstract] [Full Text] [PDF]

				J. S. Aveyard and M. A. Knowles Measurement of Relative Copy Number of CDKN2A/ARF and CDKN2B in Bladder Cancer by Real-Time Quantitative PCR and Multiplex Ligation-Dependent Probe Amplification J. Mol. Diagn., November 1, 2004; 6(4): 356 - 365. [Abstract] [Full Text] [PDF]

				M. O. Hoque, C.-C. R. Lee, P. Cairns, M. Schoenberg, and D. Sidransky Genome-Wide Genetic Characterization of Bladder Cancer: A Comparison of High-Density Single-Nucleotide Polymorphism Arrays and PCR-based Microsatellite Analysis Cancer Res., May 1, 2003; 63(9): 2216 - 2222. [Abstract] [Full Text] [PDF]

				P. Berggren, R. Kumar, S. Sakano, L. Hemminki, T. Wada, G. Steineck, J. Adolfsson, P. Larsson, U. Norming, H. Wijkstrom, et al. Detecting Homozygous Deletions in the CDKN2A(p16INK4a)/ARF(p14ARF) Gene in Urinary Bladder Cancer Using Real-Time Quantitative PCR Clin. Cancer Res., January 1, 2003; 9(1): 235 - 242. [Abstract] [Full Text] [PDF]

				L. E. Moore, A. H. Smith, C. Eng, D. Kalman, S. DeVries, V. Bhargava, K. Chew, D. Moore II, C. Ferreccio, O. A. Rey, et al. Arsenic-Related Chromosomal Alterations in Bladder Cancer J Natl Cancer Inst, November 20, 2002; 94(22): 1688 - 1696. [Abstract] [Full Text] [PDF]

				M.J. Ramirez, S. Puerto, P. Galofre, E.M. Parry, J.M. Parry, A. Creus, R. Marcos, and J. Surralles Multicolour FISH detection of radioactive iodine-induced 17cen-p53 chromosomal breakage in buccal cells from therapeutically exposed patients Carcinogenesis, August 1, 2000; 21(8): 1581 - 1586. [Abstract] [Full Text] [PDF]

				T. Wada, J. Louhelainen, K. Hemminki, J. Adolfsson, H. Wijkström, U. Norming, E. Borgström, J. Hansson, B. Sandstedt, and G. Steineck Bladder Cancer: Allelic Deletions at and around the Retinoblastoma Tumor Suppressor Gene in Relation to Stage and Grade Clin. Cancer Res., February 1, 2000; 6(2): 610 - 615. [Abstract] [Full Text]

				K. Morimura, S. Yamamoto, T. Murai, S. Mori, T.-X. Chen, H. Wanibuchi, and S. Fukushima LOH and mutational analysis of p53 alleles in mouse urinary bladder carcinomas induced by N-butyl-N-(4-hydroxybutyl) nitrosamine Carcinogenesis, April 1, 1999; 20(4): 715 - 718. [Abstract] [Full Text] [PDF]

				C A Reznikoff, C Belair, E Savelieva, Y Zhai, K Pfeifer, T Yeager, K J Thompson, S DeVries, C Bindley, and M A Newton Long-term genome stability and minimal genotypic and phenotypic alterations in HPV16 E7-, but not E6-, immortalized human uroepithelial cells. Genes & Dev., September 15, 1994; 8(18): 2227 - 2240. [Abstract] [PDF]

				R. H. Hruban, P. van der Riet, Y. S. Erozan, and D. Sidransky Molecular Biology and the Early Detection of Carcinoma of the Bladder -- The Case of Hubert H. Humphrey N. Engl. J. Med., May 5, 1994; 330(18): 1276 - 1278. [Full Text]

				E Solomon, J Borrow, and A. Goddard Chromosome aberrations and cancer Science, November 22, 1991; 254(5035): 1153 - 1160. [Abstract] [PDF]

				W. Rideout 3rd, G. Coetzee, A. Olumi, and P. Jones 5-Methylcytosine as an endogenous mutagen in the human LDL receptor and p53 genes Science, September 14, 1990; 249(4974): 1288 - 1290. [Abstract] [PDF]

				S. Baker, S Markowitz, E. Fearon, J. Willson, and B Vogelstein Suppression of human colorectal carcinoma cell growth by wild-type p53 Science, August 24, 1990; 249(4971): 912 - 915. [Abstract] [PDF]